Digital Pathology: Take Your Next Step On the Path to Implementation
Digital pathology can help overcome time, productivity, and quality constraints often associated with manual microscopy, by enabling you to work in the digital environment. Additional benefits of implementing digital pathology into your research projects are highlighted below.
Why Go Digital?
Digital pathology is the practice of converting microscopic glass slides into digital slides that can be viewed, managed, and analyzed on a computer screen or mobile device. Digital pathology is being readily adopted by research organizations to enhance biomarker and drug discovery. Here are the top reasons to implement digital pathology.
Improve Quality & Productivity
Reduced errors:
Helps prevent breaking of precious slides due to excess handling, and need to ship to distant laboratories. Misidentification may also be reduced by barcoding of slides.
More innovation:
Big data provides more research outputs for complex research questions. Allows research groups to collaborate at broader locations. Provides tools for teaching and training at different locations.
Improved analysis:
Improve accuracy in tissue analysis by removing the subjectivity and inter-/ intra-observer variability inherent in manual review, as well as providing a comprehensive, quantitative analysis.
Improved workflow:
Central storage and data management systems for digitized slides enables international collaboration, a more streamlined workflow, and for more flexible work schedules.
A new way to view:
Team annotation of slides. Measure multiple areas of interest with multiple people annotating. Get a dashboard view of all annotations for analysis. Simultaneous view of slides from the same study.
Reduced turnaround time:
Enables immediate access to archive digital slides compared to searching in physical repositories. Also reduces time in retrieving, matching and organizing data within a study.
For research use only. Not for use in diagnostic procedures
About the presenter
Rhian is a Scientist from Swansea University in Medical and Healthcare Studies and was featured in several collaborative publications. Rhian’s research-based background focused on tissue-based pathology in Multiple Sclerosis, primarily using immunohistochemical analysis and in vitro molecular techniques. She spent a short period conducting routine PCR testing for COVID-19 at the end of 2020.
Related Content
Die Inhalte des Knowledge Pathway von Leica Biosystems unterliegen den Nutzungsbedingungen der Website von Leica Biosystems, die hier eingesehen werden können: Rechtlicher Hinweis. Der Inhalt, einschließlich der Webinare, Schulungspräsentationen und ähnlicher Materialien, soll allgemeine Informationen zu bestimmten Themen liefern, die für medizinische Fachkräfte von Interesse sind. Er soll explizit nicht der medizinischen, behördlichen oder rechtlichen Beratung dienen und kann diese auch nicht ersetzen. Die Ansichten und Meinungen, die in Inhalten Dritter zum Ausdruck gebracht werden, spiegeln die persönlichen Auffassungen der Sprecher/Autoren wider und decken sich nicht notwendigerweise mit denen von Leica Biosystems, seinen Mitarbeitern oder Vertretern. Jegliche in den Inhalten enthaltene Links, die auf Quellen oder Inhalte Dritter verweisen, werden lediglich aus Gründen Ihrer Annehmlichkeit zur Verfügung gestellt.
Vor dem Gebrauch sollten die Produktinformationen, Beilagen und Bedienungsanleitungen der jeweiligen Medikamente und Geräte konsultiert werden.
Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.